Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 10/20 | 0.39 |
| ▸ | AXL | P30530 | 8/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401891 | 0.92 | MEN1 (0.42) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL2403325 | 0.91 | KCNA5 (0.51) | POLBMERTKAXLMETTYRO3 | |
| SCHEMBL6411302 | 0.88 | P2RX7 (0.40) | POLBP2RX7KCNA5PTGESPTGS2 | |
| SCHEMBL2403572 | 0.87 | KMT2A (0.41) | MERTKAXLALDH1A1SMN1; SMN2 | |
| SCHEMBL2401835 | 0.87 | MERTK (0.42) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL2579252 | 0.86 | ALDH1A1 (0.43) | POLBP2RX7MERTKAXLMET | |
| SCHEMBL2402565 | 0.85 | MERTK (0.42) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL2400337 | 0.85 | LMNA (0.45) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL2400321 | 0.85 | LMNA (0.45) | P2RX7MERTKAXLMETTYRO3 | |
| SCHEMBL6411128 | 0.83 | MERTK (0.44) | P2RX7MERTKAXLMETTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | claimed |
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | POLB 1636/4885P2RX7 1853/4885MERTK 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.